Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesHIV/AIDS Research Network Recommends Use of Abbott RealTime Viral Load Test for NIH-Sponsored Clinical Trials
Abbott, 05/08/09
The Abbott RealTime HIV-1 Assay and Abbott m2000 System have been recommended as a standard protocol for viral load testing in HIV/AIDS clinical trials sponsored by the National Institutes of Health . This recommendation was made by the Cross-Network Laboratory Focus Group (LFG), which consists of representatives from five of the NIH-sponsored HIV/AIDS clinical trials networks. The LFG recently issued a consensus statement, which was reviewed and approved by the leadership of the five networks, recommending the use of the Abbott RealTime HIV-1 assay and m2000 system for upcoming clinical trials in 2009 and beyond that have a primary focus on viral load measurements.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin
Cancer Chemotherapy and Pharmacology, 12/11/09
Data Presented at San Antonio Breast Cancer Symposium Demonstrate Treatment with Denosumab is Superior to the Standard of Care
Amgen, 12/11/09
Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors
Journal of Clinical Oncology, 12/10/09
Today in Major Studies...keeping you current
Receive free subspecialty "5-minute updates" via email
Evaluation of Treatment Satisfaction in Children with Allergic Disease Treated with an Antihistamine: An International, Non-Interventional, Retrospective Study
Clinical Drug Investigation, 12/11/09
Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded in Latin America
Sanofi-aventis, 12/10/09
Allos Therapeutics' FOLOTYN Shows Activity in a Dose Finding Phase 1 Study of Relapsed or Refractory Cutaneous T-Cell Lymphoma
Allos Therapeutics, 12/09/09
Sponsor
Article Search
Sponsor
Sponsor